EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression.

Stephanie LheureuxAna OakninSwati GargJeffrey P BruceAinhoa MadariagaNeesha C DhaniValerie BoweringJustin WhiteSarah AccardiQian TanMarsela BraunsteinKatherine KarakasisIulia CirlanStephanie PedersenTiantiam LiLorena Fariñas-MadridYeh Chen LeeZhihui Amy LiuTrevor J PughAmit M Oza

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

This is currently the largest post-PARPi study identifying genomic mechanisms of resistance to PARPis. In this setting, the activity of cediranib-olaparib varied according to the PARPi resistance mechanism.

Keyphrases

open label
clinical trial
dna damage
phase ii
study protocol
cross sectional
phase iii
randomized controlled trial
oxidative stress
gene expression